Retatrutide and Body Composition: Preserving Muscle While Losing 28% of Body Weight

Losing 28% of your body weight sounds transformative. For a 240 lb person, that's 67 lbs gone. But here's the uncomfortable question: how much of that 67 lbs is fat, and how much is muscle?

The answer matters enormously. Muscle isn't just about aesthetics — it's about metabolic health, functional capacity, injury prevention, and long-term weight maintenance. Lose too much muscle during pharmacological weight loss, and you trade one health problem (obesity) for another (sarcopenia).

This article examines what the clinical data says about retatrutide's effect on body composition and what fitness professionals can do about it.

The Lean Mass Loss Problem

All GLP-1-based medications cause lean mass loss proportional to total weight loss. This has been documented across semaglutide, tirzepatide, and retatrutide trials. The Phase 2 retatrutide data showed:

• Total fat mass reduction: up to 26.1% at 8 mg over 36 weeks
• Total lean mass reduction: proportional to total weight loss
• The fat-to-lean ratio was comparable to other GLP-1 agonists

The glucagon receptor activation (unique to retatrutide) was hypothesized to improve the fat-to-lean ratio by increasing energy expenditure and promoting fat oxidation. Phase 2 data showed a numerical trend in this direction, but it was not statistically significant.

In plain terms: retatrutide doesn't appear to be worse than semaglutide or tirzepatide for muscle preservation, but it's not meaningfully better either. The sheer magnitude of weight loss means more absolute lean mass is lost simply because more total weight is lost.

Why This Matters More at 28% Weight Loss

At 15% weight loss (semaglutide), a 200 lb person loses 30 lbs. If 25% is lean mass, that's 7.5 lbs of muscle — recoverable with focused training.

At 28% weight loss (retatrutide), the same person loses 56 lbs. If 25% is lean mass, that's 14 lbs of muscle — a much more significant functional impairment that's harder to rebuild, especially if the person is older.

The math is unforgiving: the more total weight lost, the more muscle is at risk, even if the fat-to-lean ratio stays constant.

The Protein Imperative

The single most effective intervention for preserving lean mass during pharmacological weight loss is dietary protein. Evidence-based recommendations:

• 1.6-2.2 g per kg body weight per day — significantly higher than the RDA (0.8 g/kg)
• For a 200 lb (91 kg) person: 145-200 g protein per day
• Distribute across 4-5 meals with 20-40 g per meal
• Leucine threshold: each meal should contain 2.5-3 g leucine to maximally stimulate muscle protein synthesis

The challenge: retatrutide suppresses appetite aggressively. Clients who struggle to eat enough will struggle even more to hit protein targets. This is where protein supplementation (whey, casein, plant-based blends) becomes essential, not optional.

Resistance Training: The Muscle Retention Signal

Dietary protein provides the building blocks. Resistance training provides the signal to use them.

The evidence for resistance training during GLP-1-mediated weight loss shows:

• Resistance training preserves 1.5-2x more lean mass compared to diet alone
• Compound movements (squat, deadlift, press, row) provide the strongest muscle retention signal
• Training close to failure (1-2 RIR) is more effective than moderate intensity for muscle preservation
• Frequency matters: 3-5 sessions per week is optimal during aggressive weight loss

Practical Programming for Retatrutide Clients

Weeks 1-4 (Titration): Focus on habit establishment. 3 resistance sessions, moderate volume. Protein targets at 1.6 g/kg. Expect GI disruption.

Weeks 5-16 (Active Loss): Ramp to 4-5 resistance sessions. Progressive overload. Protein at 1.8-2.0 g/kg. Adjust cardiovascular training based on energy levels.

Weeks 17-52 (Sustained Loss): Monitor body composition changes every 4-6 weeks. Adjust programming as weight drops. Consider increasing protein to 2.0-2.2 g/kg as appetite suppression intensifies.

Post-treatment (if discontinued): Expect some weight regain (5-15%). Shift to maintenance-focused programming with higher caloric targets.

The AI Programming Advantage

Static programming fails during retatrutide treatment because the client's body is changing too fast for a 12-week plan to remain relevant. AI-driven tools that adjust weekly — like EvoFit Trainer — can modify intensity, volume, and nutritional targets in response to real-time body composition and performance data.

References

1. Jastrebroff et al. (2023). NEJM, 389(6), 514-526. DOI: 10.1056/NEJMoa2301972
2. TRIUMPH-4 Phase 3 body composition data. Eli Lilly (2025).
3. Lopez et al. (2024). Muscle preservation during GLP-1 treatment. Obesity Reviews.
4. ACSM Position Stand: Nutrition and Athletic Performance (2023).
5. Morton et al. (2024). Protein requirements during caloric restriction. J Nutr.

This article is for informational purposes only and does not constitute medical advice.